RecruitingNot ApplicableNCT06025448

Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability?

From Cuff Arthropathy to Reverse Shoulder Arthroplasty - a Multicentre Randomized Control Trial (CARS 2: Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability Measured With CT-based Motion Analysis (CTMA)?).


Sponsor

Lovisenberg Diakonale Hospital

Enrollment

20 participants

Start Date

Oct 30, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial will investigate whether metallic lateralization in reverse shoulder arthroplasty is as stable as bony lateralization during the first two postsurgical years, measured with CT-based motion analysis (CTMA).


Eligibility

Min Age: 45 YearsMax Age: 80 Years

Inclusion Criteria3

  • Eligible for primary RSA due to OA, massive RC tear, failed RC repair or post-instability osteoarthritis
  • massive glenoid medialization
  • Able to read or write Norwegian

Exclusion Criteria8

  • Severe osteoporosis
  • Osteonecrosis of the humeral head
  • Dementia
  • Poor deltoid function
  • Revision surgery
  • ASA IV
  • Suspected chronic infection
  • Acute fracture

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBIO-RSA

Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using bony lateralization (BIO-RSA).

PROCEDUREMIO-RSA

Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using metallic lateralization (MIO-RSA).


Locations(1)

Lovisenberg Diaconal Hospital

Oslo, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06025448


Related Trials